Isavuconazole treatment of a patient with disseminated mucormycosis
Related Experiment Video
Updated: May 4, 2026

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
Published on: March 14, 2014
Driele Peixoto1, Lisa S Gagne, Sarah P Hammond
1Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Abstract:
We report a patient with relapsed acute myelogenous leukemia after allogeneic stem cell transplantation who developed disseminated mucormycosis due to Rhizomucor pusillus/R. miehei involving lung, brain, and skin. After failing posaconazole and being intolerant to amphotericin, he was treated effectively with isavuconazole for over 6 months despite ongoing treatment for relapsed leukemia.
More Related Videos
Related Concept Videos
Antifungal Agents
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs for Treatment of Ulcerative Colitis in IBD
Dosage Regimen: Multiple Oral Dosage
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Cystic Fibrosis: Management
Sinus disease and chronic...

